Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.20.1
Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Operating expenses:    
Research and development $ 5,104,441 $ 4,107,140
General and administrative 2,959,900 2,254,593
Total operating expenses 8,064,341 6,361,733
Loss from operations (8,064,341) (6,361,733)
Other income:    
Interest income 70,022 149,119
Change in fair value of warrant liabilities 415,833 17,799,629
Total other income 485,855 17,948,748
Net (loss) income $ (7,578,486) $ 11,587,015
Per share information:    
Net (loss) income per share of common stock, basic and diluted $ (0.49) $ 1.46
Basic and diluted weighted average shares outstanding 15,332,042 7,940,931